nodes	percent_of_prediction	percent_of_DWPC	metapath
Trifluoperazine—XDH—Doxorubicin—thyroid cancer	0.188	0.475	CbGbCtD
Trifluoperazine—HTR2C—Sorafenib—thyroid cancer	0.111	0.28	CbGbCtD
Trifluoperazine—CYP1A2—Sorafenib—thyroid cancer	0.0405	0.102	CbGbCtD
Trifluoperazine—ABCB1—Sorafenib—thyroid cancer	0.0354	0.0891	CbGbCtD
Trifluoperazine—Keratopathy—Vandetanib—thyroid cancer	0.0291	0.128	CcSEcCtD
Trifluoperazine—Corneal deposits—Vandetanib—thyroid cancer	0.0215	0.0952	CcSEcCtD
Trifluoperazine—ABCB1—Doxorubicin—thyroid cancer	0.0215	0.0541	CbGbCtD
Trifluoperazine—Brain oedema—Vandetanib—thyroid cancer	0.0138	0.0608	CcSEcCtD
Trifluoperazine—S100A4—neck—thyroid cancer	0.0102	0.0836	CbGeAlD
Trifluoperazine—S100A4—saliva-secreting gland—thyroid cancer	0.00799	0.0652	CbGeAlD
Trifluoperazine—Sudden death—Vandetanib—thyroid cancer	0.00768	0.034	CcSEcCtD
Trifluoperazine—EBPL—thyroid gland—thyroid cancer	0.00617	0.0504	CbGeAlD
Trifluoperazine—S100A4—trachea—thyroid cancer	0.00616	0.0503	CbGeAlD
Trifluoperazine—Torsade de pointes—Vandetanib—thyroid cancer	0.00561	0.0248	CcSEcCtD
Trifluoperazine—Ileus—Vandetanib—thyroid cancer	0.00556	0.0246	CcSEcCtD
Trifluoperazine—EBPL—head—thyroid cancer	0.00548	0.0447	CbGeAlD
Trifluoperazine—Ventricular arrhythmia—Vandetanib—thyroid cancer	0.00531	0.0235	CcSEcCtD
Trifluoperazine—CALY—head—thyroid cancer	0.00501	0.0409	CbGeAlD
Trifluoperazine—S100A4—thyroid gland—thyroid cancer	0.00487	0.0398	CbGeAlD
Trifluoperazine—S100A4—head—thyroid cancer	0.00432	0.0353	CbGeAlD
Trifluoperazine—TNNC1—thyroid gland—thyroid cancer	0.0041	0.0335	CbGeAlD
Trifluoperazine—EBPL—lymph node—thyroid cancer	0.00384	0.0313	CbGeAlD
Trifluoperazine—CALY—lymph node—thyroid cancer	0.00351	0.0286	CbGeAlD
Trifluoperazine—S100A4—lymph node—thyroid cancer	0.00303	0.0247	CbGeAlD
Trifluoperazine—CALM2—neck—thyroid cancer	0.00295	0.0241	CbGeAlD
Trifluoperazine—Pigmentation disorder—Epirubicin—thyroid cancer	0.00294	0.013	CcSEcCtD
Trifluoperazine—CALM1—neck—thyroid cancer	0.00293	0.024	CbGeAlD
Trifluoperazine—CALM3—saliva-secreting gland—thyroid cancer	0.00293	0.0239	CbGeAlD
Trifluoperazine—Hypoglycaemia—Vandetanib—thyroid cancer	0.00292	0.0129	CcSEcCtD
Trifluoperazine—Pigmentation disorder—Doxorubicin—thyroid cancer	0.00272	0.012	CcSEcCtD
Trifluoperazine—Cardiac arrest—Vandetanib—thyroid cancer	0.00271	0.012	CcSEcCtD
Trifluoperazine—SIGMAR1—saliva-secreting gland—thyroid cancer	0.00262	0.0214	CbGeAlD
Trifluoperazine—HTR6—head—thyroid cancer	0.0026	0.0213	CbGeAlD
Trifluoperazine—TNNC1—lymph node—thyroid cancer	0.00255	0.0208	CbGeAlD
Trifluoperazine—Dysphagia—Vandetanib—thyroid cancer	0.00247	0.0109	CcSEcCtD
Trifluoperazine—Bronchospasm—Vandetanib—thyroid cancer	0.00243	0.0107	CcSEcCtD
Trifluoperazine—Gynaecomastia—Sorafenib—thyroid cancer	0.00237	0.0105	CcSEcCtD
Trifluoperazine—CALM2—saliva-secreting gland—thyroid cancer	0.0023	0.0188	CbGeAlD
Trifluoperazine—CALM1—saliva-secreting gland—thyroid cancer	0.00229	0.0187	CbGeAlD
Trifluoperazine—CALM3—trachea—thyroid cancer	0.00226	0.0184	CbGeAlD
Trifluoperazine—Photosensitivity reaction—Vandetanib—thyroid cancer	0.00225	0.00995	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Vandetanib—thyroid cancer	0.00223	0.00984	CcSEcCtD
Trifluoperazine—Eczema—Sorafenib—thyroid cancer	0.00214	0.00947	CcSEcCtD
Trifluoperazine—Dermatitis exfoliative—Sorafenib—thyroid cancer	0.00204	0.00902	CcSEcCtD
Trifluoperazine—SIGMAR1—trachea—thyroid cancer	0.00202	0.0165	CbGeAlD
Trifluoperazine—HTR2A—neck—thyroid cancer	0.00179	0.0146	CbGeAlD
Trifluoperazine—CALM3—thyroid gland—thyroid cancer	0.00179	0.0146	CbGeAlD
Trifluoperazine—CALM2—trachea—thyroid cancer	0.00177	0.0145	CbGeAlD
Trifluoperazine—CALM1—trachea—thyroid cancer	0.00177	0.0144	CbGeAlD
Trifluoperazine—Dysphagia—Sorafenib—thyroid cancer	0.00166	0.00736	CcSEcCtD
Trifluoperazine—Muscle spasms—Vandetanib—thyroid cancer	0.00165	0.00731	CcSEcCtD
Trifluoperazine—Vision blurred—Vandetanib—thyroid cancer	0.00162	0.00716	CcSEcCtD
Trifluoperazine—Tremor—Vandetanib—thyroid cancer	0.00161	0.00712	CcSEcCtD
Trifluoperazine—SIGMAR1—thyroid gland—thyroid cancer	0.0016	0.013	CbGeAlD
Trifluoperazine—CHRM2—head—thyroid cancer	0.00156	0.0127	CbGeAlD
Trifluoperazine—Erectile dysfunction—Sorafenib—thyroid cancer	0.00153	0.00678	CcSEcCtD
Trifluoperazine—HTR2C—head—thyroid cancer	0.0015	0.0123	CbGeAlD
Trifluoperazine—Cough—Vandetanib—thyroid cancer	0.0015	0.00663	CcSEcCtD
Trifluoperazine—Convulsion—Vandetanib—thyroid cancer	0.00149	0.00658	CcSEcCtD
Trifluoperazine—Jaundice—Sorafenib—thyroid cancer	0.00145	0.00639	CcSEcCtD
Trifluoperazine—Dry mouth—Vandetanib—thyroid cancer	0.00143	0.00633	CcSEcCtD
Trifluoperazine—CALM2—thyroid gland—thyroid cancer	0.0014	0.0115	CbGeAlD
Trifluoperazine—CALM1—thyroid gland—thyroid cancer	0.0014	0.0114	CbGeAlD
Trifluoperazine—Ileus—Epirubicin—thyroid cancer	0.00139	0.00612	CcSEcCtD
Trifluoperazine—Skin disorder—Vandetanib—thyroid cancer	0.00136	0.00602	CcSEcCtD
Trifluoperazine—Ventricular arrhythmia—Epirubicin—thyroid cancer	0.00132	0.00585	CcSEcCtD
Trifluoperazine—HRH1—trachea—thyroid cancer	0.00129	0.0105	CbGeAlD
Trifluoperazine—Ileus—Doxorubicin—thyroid cancer	0.00128	0.00566	CcSEcCtD
Trifluoperazine—Insomnia—Vandetanib—thyroid cancer	0.00127	0.00561	CcSEcCtD
Trifluoperazine—HTR1A—head—thyroid cancer	0.00127	0.0103	CbGeAlD
Trifluoperazine—Dyspnoea—Vandetanib—thyroid cancer	0.00125	0.00553	CcSEcCtD
Trifluoperazine—CALM2—head—thyroid cancer	0.00124	0.0102	CbGeAlD
Trifluoperazine—CALM1—head—thyroid cancer	0.00124	0.0101	CbGeAlD
Trifluoperazine—Ventricular arrhythmia—Doxorubicin—thyroid cancer	0.00123	0.00542	CcSEcCtD
Trifluoperazine—Decreased appetite—Vandetanib—thyroid cancer	0.00122	0.00539	CcSEcCtD
Trifluoperazine—Glycosuria—Epirubicin—thyroid cancer	0.00121	0.00535	CcSEcCtD
Trifluoperazine—Fatigue—Vandetanib—thyroid cancer	0.00121	0.00535	CcSEcCtD
Trifluoperazine—Constipation—Vandetanib—thyroid cancer	0.0012	0.0053	CcSEcCtD
Trifluoperazine—Blood disorder—Epirubicin—thyroid cancer	0.00117	0.00519	CcSEcCtD
Trifluoperazine—ADRA1A—head—thyroid cancer	0.00117	0.00953	CbGeAlD
Trifluoperazine—Liver injury—Epirubicin—thyroid cancer	0.00117	0.00515	CcSEcCtD
Trifluoperazine—Erythema—Sorafenib—thyroid cancer	0.00116	0.00513	CcSEcCtD
Trifluoperazine—DRD2—head—thyroid cancer	0.00114	0.00934	CbGeAlD
Trifluoperazine—Glycosuria—Doxorubicin—thyroid cancer	0.00112	0.00495	CcSEcCtD
Trifluoperazine—Amenorrhoea—Epirubicin—thyroid cancer	0.00112	0.00493	CcSEcCtD
Trifluoperazine—Muscle spasms—Sorafenib—thyroid cancer	0.00111	0.00493	CcSEcCtD
Trifluoperazine—CALM3—lymph node—thyroid cancer	0.00111	0.00906	CbGeAlD
Trifluoperazine—Body temperature increased—Vandetanib—thyroid cancer	0.00111	0.0049	CcSEcCtD
Trifluoperazine—CYP1A2—thyroid gland—thyroid cancer	0.00109	0.00888	CbGeAlD
Trifluoperazine—Blood disorder—Doxorubicin—thyroid cancer	0.00109	0.0048	CcSEcCtD
Trifluoperazine—Liver injury—Doxorubicin—thyroid cancer	0.00108	0.00476	CcSEcCtD
Trifluoperazine—HTR2A—trachea—thyroid cancer	0.00108	0.00878	CbGeAlD
Trifluoperazine—Angioedema—Sorafenib—thyroid cancer	0.00106	0.00468	CcSEcCtD
Trifluoperazine—Dyskinesia—Epirubicin—thyroid cancer	0.00104	0.00461	CcSEcCtD
Trifluoperazine—Leukopenia—Sorafenib—thyroid cancer	0.00104	0.00459	CcSEcCtD
Trifluoperazine—Amenorrhoea—Doxorubicin—thyroid cancer	0.00103	0.00456	CcSEcCtD
Trifluoperazine—Cough—Sorafenib—thyroid cancer	0.00101	0.00447	CcSEcCtD
Trifluoperazine—Asthenia—Vandetanib—thyroid cancer	0.00101	0.00445	CcSEcCtD
Trifluoperazine—Gait disturbance—Epirubicin—thyroid cancer	0.001	0.00444	CcSEcCtD
Trifluoperazine—Pruritus—Vandetanib—thyroid cancer	0.000993	0.00439	CcSEcCtD
Trifluoperazine—SIGMAR1—lymph node—thyroid cancer	0.000992	0.0081	CbGeAlD
Trifluoperazine—Hepatocellular injury—Epirubicin—thyroid cancer	0.00098	0.00433	CcSEcCtD
Trifluoperazine—Dry mouth—Sorafenib—thyroid cancer	0.000966	0.00427	CcSEcCtD
Trifluoperazine—Dyskinesia—Doxorubicin—thyroid cancer	0.000965	0.00427	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Sorafenib—thyroid cancer	0.000946	0.00418	CcSEcCtD
Trifluoperazine—Gait disturbance—Doxorubicin—thyroid cancer	0.000929	0.00411	CcSEcCtD
Trifluoperazine—Dizziness—Vandetanib—thyroid cancer	0.000928	0.0041	CcSEcCtD
Trifluoperazine—Aplastic anaemia—Epirubicin—thyroid cancer	0.00092	0.00407	CcSEcCtD
Trifluoperazine—Skin disorder—Sorafenib—thyroid cancer	0.000919	0.00406	CcSEcCtD
Trifluoperazine—Hepatocellular injury—Doxorubicin—thyroid cancer	0.000907	0.00401	CcSEcCtD
Trifluoperazine—HRH1—head—thyroid cancer	0.000904	0.00738	CbGeAlD
Trifluoperazine—Anorexia—Sorafenib—thyroid cancer	0.000902	0.00399	CcSEcCtD
Trifluoperazine—Rash—Vandetanib—thyroid cancer	0.000885	0.00391	CcSEcCtD
Trifluoperazine—Dermatitis—Vandetanib—thyroid cancer	0.000884	0.00391	CcSEcCtD
Trifluoperazine—Headache—Vandetanib—thyroid cancer	0.000879	0.00389	CcSEcCtD
Trifluoperazine—CALM2—lymph node—thyroid cancer	0.000872	0.00712	CbGeAlD
Trifluoperazine—CALM1—lymph node—thyroid cancer	0.000868	0.00708	CbGeAlD
Trifluoperazine—Aplastic anaemia—Doxorubicin—thyroid cancer	0.000852	0.00376	CcSEcCtD
Trifluoperazine—Dyspnoea—Sorafenib—thyroid cancer	0.000844	0.00373	CcSEcCtD
Trifluoperazine—Nausea—Vandetanib—thyroid cancer	0.000833	0.00368	CcSEcCtD
Trifluoperazine—Decreased appetite—Sorafenib—thyroid cancer	0.000823	0.00364	CcSEcCtD
Trifluoperazine—Fatigue—Sorafenib—thyroid cancer	0.000816	0.00361	CcSEcCtD
Trifluoperazine—Photosensitivity—Epirubicin—thyroid cancer	0.00081	0.00358	CcSEcCtD
Trifluoperazine—Constipation—Sorafenib—thyroid cancer	0.000809	0.00358	CcSEcCtD
Trifluoperazine—Eczema—Epirubicin—thyroid cancer	0.000792	0.0035	CcSEcCtD
Trifluoperazine—Increased appetite—Epirubicin—thyroid cancer	0.000757	0.00335	CcSEcCtD
Trifluoperazine—HTR2A—head—thyroid cancer	0.000755	0.00616	CbGeAlD
Trifluoperazine—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.000754	0.00333	CcSEcCtD
Trifluoperazine—Urticaria—Sorafenib—thyroid cancer	0.000752	0.00332	CcSEcCtD
Trifluoperazine—Photosensitivity—Doxorubicin—thyroid cancer	0.00075	0.00331	CcSEcCtD
Trifluoperazine—Body temperature increased—Sorafenib—thyroid cancer	0.000748	0.00331	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000735	0.00325	CcSEcCtD
Trifluoperazine—Eczema—Doxorubicin—thyroid cancer	0.000733	0.00324	CcSEcCtD
Trifluoperazine—Hypoglycaemia—Epirubicin—thyroid cancer	0.000729	0.00322	CcSEcCtD
Trifluoperazine—ABCB1—trachea—thyroid cancer	0.000705	0.00575	CbGeAlD
Trifluoperazine—Increased appetite—Doxorubicin—thyroid cancer	0.000701	0.0031	CcSEcCtD
Trifluoperazine—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.000698	0.00308	CcSEcCtD
Trifluoperazine—Hypersensitivity—Sorafenib—thyroid cancer	0.000697	0.00308	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.00068	0.00301	CcSEcCtD
Trifluoperazine—Asthenia—Sorafenib—thyroid cancer	0.000679	0.003	CcSEcCtD
Trifluoperazine—Cardiac arrest—Epirubicin—thyroid cancer	0.000677	0.00299	CcSEcCtD
Trifluoperazine—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000675	0.00298	CcSEcCtD
Trifluoperazine—Pruritus—Sorafenib—thyroid cancer	0.00067	0.00296	CcSEcCtD
Trifluoperazine—HRH1—lymph node—thyroid cancer	0.000633	0.00517	CbGeAlD
Trifluoperazine—Muscular weakness—Epirubicin—thyroid cancer	0.000628	0.00277	CcSEcCtD
Trifluoperazine—Cardiac arrest—Doxorubicin—thyroid cancer	0.000626	0.00277	CcSEcCtD
Trifluoperazine—Dizziness—Sorafenib—thyroid cancer	0.000626	0.00277	CcSEcCtD
Trifluoperazine—Asthma—Epirubicin—thyroid cancer	0.000615	0.00272	CcSEcCtD
Trifluoperazine—Dysphagia—Epirubicin—thyroid cancer	0.000615	0.00272	CcSEcCtD
Trifluoperazine—Eosinophilia—Epirubicin—thyroid cancer	0.000609	0.00269	CcSEcCtD
Trifluoperazine—Rash—Sorafenib—thyroid cancer	0.000597	0.00264	CcSEcCtD
Trifluoperazine—Dermatitis—Sorafenib—thyroid cancer	0.000596	0.00264	CcSEcCtD
Trifluoperazine—Headache—Sorafenib—thyroid cancer	0.000593	0.00262	CcSEcCtD
Trifluoperazine—Pancytopenia—Epirubicin—thyroid cancer	0.000584	0.00258	CcSEcCtD
Trifluoperazine—Muscular weakness—Doxorubicin—thyroid cancer	0.000581	0.00257	CcSEcCtD
Trifluoperazine—Asthma—Doxorubicin—thyroid cancer	0.000569	0.00252	CcSEcCtD
Trifluoperazine—Dysphagia—Doxorubicin—thyroid cancer	0.000569	0.00252	CcSEcCtD
Trifluoperazine—Eosinophilia—Doxorubicin—thyroid cancer	0.000563	0.00249	CcSEcCtD
Trifluoperazine—Nausea—Sorafenib—thyroid cancer	0.000562	0.00248	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000561	0.00248	CcSEcCtD
Trifluoperazine—Weight increased—Epirubicin—thyroid cancer	0.00056	0.00247	CcSEcCtD
Trifluoperazine—ABCB1—thyroid gland—thyroid cancer	0.000558	0.00455	CbGeAlD
Trifluoperazine—Hyperglycaemia—Epirubicin—thyroid cancer	0.000555	0.00245	CcSEcCtD
Trifluoperazine—Drowsiness—Epirubicin—thyroid cancer	0.000548	0.00242	CcSEcCtD
Trifluoperazine—Pancytopenia—Doxorubicin—thyroid cancer	0.00054	0.00239	CcSEcCtD
Trifluoperazine—Jaundice—Epirubicin—thyroid cancer	0.000535	0.00236	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000519	0.0023	CcSEcCtD
Trifluoperazine—Weight increased—Doxorubicin—thyroid cancer	0.000518	0.00229	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000513	0.00227	CcSEcCtD
Trifluoperazine—Agranulocytosis—Epirubicin—thyroid cancer	0.000512	0.00226	CcSEcCtD
Trifluoperazine—Drowsiness—Doxorubicin—thyroid cancer	0.000507	0.00224	CcSEcCtD
Trifluoperazine—ABCB1—head—thyroid cancer	0.000495	0.00404	CbGeAlD
Trifluoperazine—Jaundice—Doxorubicin—thyroid cancer	0.000495	0.00219	CcSEcCtD
Trifluoperazine—Oedema peripheral—Epirubicin—thyroid cancer	0.000485	0.00214	CcSEcCtD
Trifluoperazine—Agranulocytosis—Doxorubicin—thyroid cancer	0.000474	0.00209	CcSEcCtD
Trifluoperazine—Oedema peripheral—Doxorubicin—thyroid cancer	0.000449	0.00198	CcSEcCtD
Trifluoperazine—Erythema—Epirubicin—thyroid cancer	0.000429	0.00189	CcSEcCtD
Trifluoperazine—Nervousness—Epirubicin—thyroid cancer	0.000416	0.00184	CcSEcCtD
Trifluoperazine—Muscle spasms—Epirubicin—thyroid cancer	0.000412	0.00182	CcSEcCtD
Trifluoperazine—Vision blurred—Epirubicin—thyroid cancer	0.000404	0.00179	CcSEcCtD
Trifluoperazine—Erythema—Doxorubicin—thyroid cancer	0.000397	0.00175	CcSEcCtD
Trifluoperazine—Agitation—Epirubicin—thyroid cancer	0.000394	0.00174	CcSEcCtD
Trifluoperazine—Nervousness—Doxorubicin—thyroid cancer	0.000385	0.0017	CcSEcCtD
Trifluoperazine—Leukopenia—Epirubicin—thyroid cancer	0.000384	0.0017	CcSEcCtD
Trifluoperazine—Muscle spasms—Doxorubicin—thyroid cancer	0.000381	0.00169	CcSEcCtD
Trifluoperazine—Cough—Epirubicin—thyroid cancer	0.000374	0.00165	CcSEcCtD
Trifluoperazine—Vision blurred—Doxorubicin—thyroid cancer	0.000374	0.00165	CcSEcCtD
Trifluoperazine—Convulsion—Epirubicin—thyroid cancer	0.000371	0.00164	CcSEcCtD
Trifluoperazine—Agitation—Doxorubicin—thyroid cancer	0.000364	0.00161	CcSEcCtD
Trifluoperazine—Dry mouth—Epirubicin—thyroid cancer	0.000357	0.00158	CcSEcCtD
Trifluoperazine—Leukopenia—Doxorubicin—thyroid cancer	0.000355	0.00157	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Epirubicin—thyroid cancer	0.00035	0.00155	CcSEcCtD
Trifluoperazine—ABCB1—lymph node—thyroid cancer	0.000346	0.00283	CbGeAlD
Trifluoperazine—Cough—Doxorubicin—thyroid cancer	0.000346	0.00153	CcSEcCtD
Trifluoperazine—Convulsion—Doxorubicin—thyroid cancer	0.000344	0.00152	CcSEcCtD
Trifluoperazine—Skin disorder—Epirubicin—thyroid cancer	0.00034	0.0015	CcSEcCtD
Trifluoperazine—Anorexia—Epirubicin—thyroid cancer	0.000333	0.00147	CcSEcCtD
Trifluoperazine—Dry mouth—Doxorubicin—thyroid cancer	0.00033	0.00146	CcSEcCtD
Trifluoperazine—Hypotension—Epirubicin—thyroid cancer	0.000327	0.00144	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000324	0.00143	CcSEcCtD
Trifluoperazine—Insomnia—Epirubicin—thyroid cancer	0.000316	0.0014	CcSEcCtD
Trifluoperazine—Skin disorder—Doxorubicin—thyroid cancer	0.000314	0.00139	CcSEcCtD
Trifluoperazine—Dyspnoea—Epirubicin—thyroid cancer	0.000312	0.00138	CcSEcCtD
Trifluoperazine—Somnolence—Epirubicin—thyroid cancer	0.000311	0.00137	CcSEcCtD
Trifluoperazine—Anorexia—Doxorubicin—thyroid cancer	0.000308	0.00136	CcSEcCtD
Trifluoperazine—Decreased appetite—Epirubicin—thyroid cancer	0.000304	0.00134	CcSEcCtD
Trifluoperazine—Hypotension—Doxorubicin—thyroid cancer	0.000302	0.00134	CcSEcCtD
Trifluoperazine—Fatigue—Epirubicin—thyroid cancer	0.000302	0.00133	CcSEcCtD
Trifluoperazine—Constipation—Epirubicin—thyroid cancer	0.000299	0.00132	CcSEcCtD
Trifluoperazine—Insomnia—Doxorubicin—thyroid cancer	0.000293	0.00129	CcSEcCtD
Trifluoperazine—Dyspnoea—Doxorubicin—thyroid cancer	0.000289	0.00128	CcSEcCtD
Trifluoperazine—Somnolence—Doxorubicin—thyroid cancer	0.000288	0.00127	CcSEcCtD
Trifluoperazine—Decreased appetite—Doxorubicin—thyroid cancer	0.000281	0.00124	CcSEcCtD
Trifluoperazine—Fatigue—Doxorubicin—thyroid cancer	0.000279	0.00123	CcSEcCtD
Trifluoperazine—Urticaria—Epirubicin—thyroid cancer	0.000278	0.00123	CcSEcCtD
Trifluoperazine—Constipation—Doxorubicin—thyroid cancer	0.000277	0.00122	CcSEcCtD
Trifluoperazine—Body temperature increased—Epirubicin—thyroid cancer	0.000276	0.00122	CcSEcCtD
Trifluoperazine—Hypersensitivity—Epirubicin—thyroid cancer	0.000258	0.00114	CcSEcCtD
Trifluoperazine—Urticaria—Doxorubicin—thyroid cancer	0.000257	0.00114	CcSEcCtD
Trifluoperazine—Body temperature increased—Doxorubicin—thyroid cancer	0.000256	0.00113	CcSEcCtD
Trifluoperazine—Asthenia—Epirubicin—thyroid cancer	0.000251	0.00111	CcSEcCtD
Trifluoperazine—Pruritus—Epirubicin—thyroid cancer	0.000247	0.00109	CcSEcCtD
Trifluoperazine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000238	0.00105	CcSEcCtD
Trifluoperazine—Asthenia—Doxorubicin—thyroid cancer	0.000232	0.00103	CcSEcCtD
Trifluoperazine—Dizziness—Epirubicin—thyroid cancer	0.000231	0.00102	CcSEcCtD
Trifluoperazine—Pruritus—Doxorubicin—thyroid cancer	0.000229	0.00101	CcSEcCtD
Trifluoperazine—Rash—Epirubicin—thyroid cancer	0.000221	0.000975	CcSEcCtD
Trifluoperazine—Dermatitis—Epirubicin—thyroid cancer	0.00022	0.000974	CcSEcCtD
Trifluoperazine—Headache—Epirubicin—thyroid cancer	0.000219	0.000969	CcSEcCtD
Trifluoperazine—Dizziness—Doxorubicin—thyroid cancer	0.000214	0.000946	CcSEcCtD
Trifluoperazine—Nausea—Epirubicin—thyroid cancer	0.000208	0.000918	CcSEcCtD
Trifluoperazine—Rash—Doxorubicin—thyroid cancer	0.000204	0.000902	CcSEcCtD
Trifluoperazine—Dermatitis—Doxorubicin—thyroid cancer	0.000204	0.000901	CcSEcCtD
Trifluoperazine—Headache—Doxorubicin—thyroid cancer	0.000203	0.000896	CcSEcCtD
Trifluoperazine—Nausea—Doxorubicin—thyroid cancer	0.000192	0.00085	CcSEcCtD
Trifluoperazine—Antrafenine—PTGS2—thyroid cancer	3.46e-05	1	CrCbGaD
Trifluoperazine—CALM2—Adaptive Immune System—NRAS—thyroid cancer	2.16e-05	8.49e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—NRAS—thyroid cancer	2.16e-05	8.49e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—TERT—thyroid cancer	2.15e-05	8.46e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Hemostasis—KRAS—thyroid cancer	2.15e-05	8.45e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Hemostasis—KRAS—thyroid cancer	2.15e-05	8.45e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—TERT—thyroid cancer	2.12e-05	8.33e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—TERT—thyroid cancer	2.11e-05	8.31e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—TERT—thyroid cancer	2.08e-05	8.18e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—TERT—thyroid cancer	2.07e-05	8.15e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—NRAS—thyroid cancer	2.07e-05	8.12e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—HIF1A—thyroid cancer	2.06e-05	8.09e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—NRAS—thyroid cancer	2.06e-05	8.08e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—RXRA—thyroid cancer	2.05e-05	8.07e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling by GPCR—HRAS—thyroid cancer	2.04e-05	8.03e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—HIF1A—thyroid cancer	2.03e-05	7.96e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—HIF1A—thyroid cancer	2.02e-05	7.95e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—KRAS—thyroid cancer	2e-05	7.86e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—HIF1A—thyroid cancer	1.99e-05	7.82e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—BRAF—thyroid cancer	1.99e-05	7.82e-05	CbGpPWpGaD
Trifluoperazine—HTR6—GPCR downstream signaling—AKT1—thyroid cancer	1.99e-05	7.8e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—HIF1A—thyroid cancer	1.98e-05	7.8e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Hemostasis—TP53—thyroid cancer	1.97e-05	7.76e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—NRG1—thyroid cancer	1.96e-05	7.7e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.95e-05	7.67e-05	CbGpPWpGaD
Trifluoperazine—UGT1A4—Metabolism—AKT1—thyroid cancer	1.94e-05	7.64e-05	CbGpPWpGaD
Trifluoperazine—XDH—Metabolism—AKT1—thyroid cancer	1.94e-05	7.64e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—BRAF—thyroid cancer	1.94e-05	7.63e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—KRAS—thyroid cancer	1.93e-05	7.61e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—KRAS—thyroid cancer	1.93e-05	7.61e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—BRAF—thyroid cancer	1.93e-05	7.59e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—BRAF—thyroid cancer	1.92e-05	7.56e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—BRAF—thyroid cancer	1.92e-05	7.56e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—KRAS—thyroid cancer	1.92e-05	7.55e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—CCND1—thyroid cancer	1.91e-05	7.53e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Hemostasis—TP53—thyroid cancer	1.91e-05	7.51e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Hemostasis—TP53—thyroid cancer	1.91e-05	7.51e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—NRG1—thyroid cancer	1.89e-05	7.45e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—NRG1—thyroid cancer	1.89e-05	7.45e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Hemostasis—HRAS—thyroid cancer	1.89e-05	7.42e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—KRAS—thyroid cancer	1.86e-05	7.3e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—KRAS—thyroid cancer	1.86e-05	7.3e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—PTEN—thyroid cancer	1.85e-05	7.26e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.83e-05	7.18e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Hemostasis—HRAS—thyroid cancer	1.83e-05	7.18e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Hemostasis—HRAS—thyroid cancer	1.83e-05	7.18e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—NRAS—thyroid cancer	1.81e-05	7.13e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling by GPCR—AKT1—thyroid cancer	1.8e-05	7.09e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—NRAS—thyroid cancer	1.78e-05	7.02e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—NRAS—thyroid cancer	1.78e-05	7e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—KRAS—thyroid cancer	1.78e-05	6.99e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—KRAS—thyroid cancer	1.77e-05	6.95e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—TERT—thyroid cancer	1.76e-05	6.91e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—NRAS—thyroid cancer	1.75e-05	6.89e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—NRAS—thyroid cancer	1.75e-05	6.87e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—PPARG—thyroid cancer	1.71e-05	6.72e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—BRAF—thyroid cancer	1.7e-05	6.7e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—TERT—thyroid cancer	1.7e-05	6.69e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—TERT—thyroid cancer	1.7e-05	6.69e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—HRAS—thyroid cancer	1.7e-05	6.68e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—HIF1A—thyroid cancer	1.68e-05	6.61e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—BRAF—thyroid cancer	1.68e-05	6.59e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—BRAF—thyroid cancer	1.67e-05	6.58e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Hemostasis—AKT1—thyroid cancer	1.67e-05	6.55e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—PPARG—thyroid cancer	1.65e-05	6.5e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—PPARG—thyroid cancer	1.65e-05	6.5e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—NRAS—thyroid cancer	1.65e-05	6.48e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—BRAF—thyroid cancer	1.65e-05	6.47e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—HRAS—thyroid cancer	1.64e-05	6.47e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—HRAS—thyroid cancer	1.64e-05	6.47e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—BRAF—thyroid cancer	1.64e-05	6.46e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—RXRA—thyroid cancer	1.64e-05	6.44e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—HRAS—thyroid cancer	1.63e-05	6.42e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—HIF1A—thyroid cancer	1.63e-05	6.39e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—HIF1A—thyroid cancer	1.63e-05	6.39e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Hemostasis—AKT1—thyroid cancer	1.61e-05	6.34e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Hemostasis—AKT1—thyroid cancer	1.61e-05	6.34e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—PTGS2—thyroid cancer	1.61e-05	6.31e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.59e-05	6.26e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—HRAS—thyroid cancer	1.58e-05	6.21e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—HRAS—thyroid cancer	1.58e-05	6.21e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—KRAS—thyroid cancer	1.56e-05	6.14e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—PTGS2—thyroid cancer	1.55e-05	6.11e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—PTGS2—thyroid cancer	1.55e-05	6.11e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—KRAS—thyroid cancer	1.54e-05	6.04e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—KRAS—thyroid cancer	1.53e-05	6.02e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—PTEN—thyroid cancer	1.52e-05	5.96e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—HRAS—thyroid cancer	1.51e-05	5.94e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—KRAS—thyroid cancer	1.51e-05	5.93e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—KRAS—thyroid cancer	1.5e-05	5.91e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—HRAS—thyroid cancer	1.5e-05	5.91e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—AKT1—thyroid cancer	1.5e-05	5.9e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—NRAS—thyroid cancer	1.48e-05	5.82e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—GPCR downstream signaling—AKT1—thyroid cancer	1.47e-05	5.78e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—PTEN—thyroid cancer	1.47e-05	5.77e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—PTEN—thyroid cancer	1.47e-05	5.77e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—GPCR downstream signaling—AKT1—thyroid cancer	1.46e-05	5.75e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—AKT1—thyroid cancer	1.45e-05	5.71e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—AKT1—thyroid cancer	1.45e-05	5.71e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—AKT1—thyroid cancer	1.44e-05	5.67e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—NRAS—thyroid cancer	1.43e-05	5.63e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—NRAS—thyroid cancer	1.43e-05	5.63e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—KRAS—thyroid cancer	1.42e-05	5.58e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—CCND1—thyroid cancer	1.42e-05	5.57e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—CCND1—thyroid cancer	1.41e-05	5.54e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—PTEN—thyroid cancer	1.4e-05	5.51e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—AKT1—thyroid cancer	1.39e-05	5.48e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—AKT1—thyroid cancer	1.39e-05	5.48e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—BRAF—thyroid cancer	1.39e-05	5.47e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—PTEN—thyroid cancer	1.37e-05	5.38e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—PTEN—thyroid cancer	1.36e-05	5.35e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—PTEN—thyroid cancer	1.35e-05	5.33e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—PTEN—thyroid cancer	1.35e-05	5.33e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—NRAS—thyroid cancer	1.35e-05	5.32e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—BRAF—thyroid cancer	1.35e-05	5.3e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—BRAF—thyroid cancer	1.35e-05	5.3e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—PTGS2—thyroid cancer	1.35e-05	5.29e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—AKT1—thyroid cancer	1.33e-05	5.25e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—AKT1—thyroid cancer	1.33e-05	5.22e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—HRAS—thyroid cancer	1.33e-05	5.22e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—NRAS—thyroid cancer	1.31e-05	5.15e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—NRAS—thyroid cancer	1.31e-05	5.15e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—HRAS—thyroid cancer	1.31e-05	5.13e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—HRAS—thyroid cancer	1.3e-05	5.12e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—PTGS2—thyroid cancer	1.3e-05	5.12e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—PTGS2—thyroid cancer	1.3e-05	5.12e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PPARG—thyroid cancer	1.3e-05	5.09e-05	CbGpPWpGaD
Trifluoperazine—DRD2—GPCR downstream signaling—AKT1—thyroid cancer	1.29e-05	5.07e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—HRAS—thyroid cancer	1.28e-05	5.04e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—HRAS—thyroid cancer	1.28e-05	5.03e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—KRAS—thyroid cancer	1.27e-05	5.01e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—GPCR downstream signaling—AKT1—thyroid cancer	1.27e-05	4.99e-05	CbGpPWpGaD
Trifluoperazine—HRH1—GPCR downstream signaling—AKT1—thyroid cancer	1.27e-05	4.98e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—TP53—thyroid cancer	1.26e-05	4.96e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—NRAS—thyroid cancer	1.25e-05	4.91e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—GPCR downstream signaling—AKT1—thyroid cancer	1.25e-05	4.9e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CCND1—thyroid cancer	1.24e-05	4.89e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—GPCR downstream signaling—AKT1—thyroid cancer	1.24e-05	4.89e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—KRAS—thyroid cancer	1.23e-05	4.85e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—KRAS—thyroid cancer	1.23e-05	4.85e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CCND1—thyroid cancer	1.22e-05	4.81e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CCND1—thyroid cancer	1.22e-05	4.8e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—NRAS—thyroid cancer	1.22e-05	4.8e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—NRAS—thyroid cancer	1.21e-05	4.77e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—NRAS—thyroid cancer	1.21e-05	4.75e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—NRAS—thyroid cancer	1.21e-05	4.75e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—HRAS—thyroid cancer	1.21e-05	4.74e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CCND1—thyroid cancer	1.2e-05	4.73e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—PTEN—thyroid cancer	1.2e-05	4.72e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CCND1—thyroid cancer	1.2e-05	4.71e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—PTEN—thyroid cancer	1.18e-05	4.65e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—PTEN—thyroid cancer	1.18e-05	4.64e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—PTEN—thyroid cancer	1.17e-05	4.61e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—AKT1—thyroid cancer	1.17e-05	4.61e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—KRAS—thyroid cancer	1.16e-05	4.58e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—PTEN—thyroid cancer	1.16e-05	4.56e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—PTEN—thyroid cancer	1.16e-05	4.55e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—AKT1—thyroid cancer	1.15e-05	4.53e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—AKT1—thyroid cancer	1.15e-05	4.52e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—PTEN—thyroid cancer	1.13e-05	4.46e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—PTEN—thyroid cancer	1.13e-05	4.46e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—AKT1—thyroid cancer	1.13e-05	4.45e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—AKT1—thyroid cancer	1.13e-05	4.44e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—KRAS—thyroid cancer	1.13e-05	4.43e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—KRAS—thyroid cancer	1.13e-05	4.43e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—HRAS—thyroid cancer	1.08e-05	4.26e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—KRAS—thyroid cancer	1.08e-05	4.23e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—NRAS—thyroid cancer	1.07e-05	4.21e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—AKT1—thyroid cancer	1.06e-05	4.19e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—NRAS—thyroid cancer	1.05e-05	4.14e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—NRAS—thyroid cancer	1.05e-05	4.14e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—KRAS—thyroid cancer	1.05e-05	4.13e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—HRAS—thyroid cancer	1.05e-05	4.12e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—HRAS—thyroid cancer	1.05e-05	4.12e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—KRAS—thyroid cancer	1.04e-05	4.11e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—KRAS—thyroid cancer	1.04e-05	4.09e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—KRAS—thyroid cancer	1.04e-05	4.09e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—NRAS—thyroid cancer	1.04e-05	4.07e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PPARG—thyroid cancer	1.03e-05	4.07e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—NRAS—thyroid cancer	1.03e-05	4.06e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PTGS2—thyroid cancer	1.02e-05	4.01e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CCND1—thyroid cancer	1.02e-05	3.99e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—HRAS—thyroid cancer	9.9e-06	3.89e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CCND1—thyroid cancer	9.83e-06	3.86e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CCND1—thyroid cancer	9.83e-06	3.86e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—PTEN—thyroid cancer	9.81e-06	3.86e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—HRAS—thyroid cancer	9.58e-06	3.77e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—HRAS—thyroid cancer	9.58e-06	3.77e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—AKT1—thyroid cancer	9.57e-06	3.76e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—PTEN—thyroid cancer	9.49e-06	3.73e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—PTEN—thyroid cancer	9.49e-06	3.73e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—TP53—thyroid cancer	9.33e-06	3.67e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—TP53—thyroid cancer	9.29e-06	3.65e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—AKT1—thyroid cancer	9.26e-06	3.64e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—AKT1—thyroid cancer	9.26e-06	3.64e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—KRAS—thyroid cancer	9.22e-06	3.62e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—HRAS—thyroid cancer	9.14e-06	3.59e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—KRAS—thyroid cancer	9.07e-06	3.57e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—KRAS—thyroid cancer	9.05e-06	3.56e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—HRAS—thyroid cancer	8.93e-06	3.51e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—KRAS—thyroid cancer	8.91e-06	3.5e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PTEN—thyroid cancer	8.89e-06	3.49e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—KRAS—thyroid cancer	8.88e-06	3.49e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—HRAS—thyroid cancer	8.88e-06	3.49e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—HRAS—thyroid cancer	8.84e-06	3.48e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—HRAS—thyroid cancer	8.84e-06	3.48e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—NRAS—thyroid cancer	8.75e-06	3.44e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—AKT1—thyroid cancer	8.74e-06	3.44e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—NRAS—thyroid cancer	8.47e-06	3.33e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—NRAS—thyroid cancer	8.47e-06	3.33e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—AKT1—thyroid cancer	8.46e-06	3.32e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—AKT1—thyroid cancer	8.46e-06	3.32e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—TP53—thyroid cancer	8.2e-06	3.22e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PTGS2—thyroid cancer	8.14e-06	3.2e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—AKT1—thyroid cancer	8.07e-06	3.17e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—TP53—thyroid cancer	8.06e-06	3.17e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—TP53—thyroid cancer	8.05e-06	3.16e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—TP53—thyroid cancer	7.92e-06	3.11e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—TP53—thyroid cancer	7.9e-06	3.1e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—AKT1—thyroid cancer	7.88e-06	3.1e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—AKT1—thyroid cancer	7.84e-06	3.08e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—HRAS—thyroid cancer	7.84e-06	3.08e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—AKT1—thyroid cancer	7.81e-06	3.07e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—AKT1—thyroid cancer	7.81e-06	3.07e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—HRAS—thyroid cancer	7.71e-06	3.03e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—HRAS—thyroid cancer	7.7e-06	3.03e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—HRAS—thyroid cancer	7.57e-06	2.98e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—HRAS—thyroid cancer	7.55e-06	2.97e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—KRAS—thyroid cancer	7.53e-06	2.96e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—KRAS—thyroid cancer	7.29e-06	2.86e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—KRAS—thyroid cancer	7.29e-06	2.86e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PTEN—thyroid cancer	7.1e-06	2.79e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—AKT1—thyroid cancer	6.92e-06	2.72e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—AKT1—thyroid cancer	6.81e-06	2.68e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—AKT1—thyroid cancer	6.8e-06	2.67e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—AKT1—thyroid cancer	6.76e-06	2.66e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—TP53—thyroid cancer	6.69e-06	2.63e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—AKT1—thyroid cancer	6.69e-06	2.63e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—AKT1—thyroid cancer	6.67e-06	2.62e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—AKT1—thyroid cancer	6.54e-06	2.57e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—AKT1—thyroid cancer	6.54e-06	2.57e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—TP53—thyroid cancer	6.48e-06	2.55e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—TP53—thyroid cancer	6.48e-06	2.55e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—HRAS—thyroid cancer	6.4e-06	2.52e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—HRAS—thyroid cancer	6.19e-06	2.43e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—HRAS—thyroid cancer	6.19e-06	2.43e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—AKT1—thyroid cancer	5.65e-06	2.22e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—AKT1—thyroid cancer	5.47e-06	2.15e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—AKT1—thyroid cancer	5.47e-06	2.15e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—AKT1—thyroid cancer	5.12e-06	2.01e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—AKT1—thyroid cancer	4.09e-06	1.61e-05	CbGpPWpGaD
